PBAC Public Summary Documents – November 2020
Page last updated: 19 March 2021
Public Summary Documents relating to the November 2020 PBAC meeting.
- Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima®
- Adalimumab: Injection 40 mg in 0.8 mL pre-filled pen, Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL vial; Idacio®
- Adrenaline I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector; I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector; I.M. injection 500 micrograms in 0.3 mL single dose syringe auto-injector; Anapen®
- Amino acid formula with vitamins and minerals without lysine and low in tryptophan: Sachets containing oral powder 24 g, Sachets containing oral powder 25 g; GA Gel®; GA Express 15®
- Apalutamide: Tablet 60 mg; Erlyand®
- Apomorphine: Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringe; Movapo PFS®
- Beclometasone dipropionate with Formoterol fumarate dehydrate and Glycopyrronium: Pressurised inhalation containing Beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses; Trimbow®
- Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Mvasi®
- Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
- Cariprazine: Capsule 1.5 mg, Capsule 3 mg, Capsule 4.5 mg, Capsule 6 mg; Reagila®
- Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
- Crisaborole: Ointment 2%, 30 g; Ointment 2%, 60 g; Staquis®
- Dapagliflozin: Tablet 10 mg; Forxiga®
- Deferasirox: Dispersible tablet 125 mg, Dispersible tablet 250 mg, Dispersible tablet 500 mg; Deferasirox Juno®
- Dupilumab (atopic dermatitis): Injection 200 mg in 1.14 mL single dose prefilled syringe, Injection 300 mg in 2 mL single dose prefilled syringe; Dupixent®
- Dupilumab (asthma): Injection 200 mg in 1.14 mL single use pre-filled syringe, Injection 300 mg in 2 mL single use pre-filled syringe; Dupixent®
- Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®
- Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris®
- Elotuzumab: Powder for I.V. infusion 300 mg, Powder for I.V. infusion 400 mg; Empliciti®
- Evolocumab: Injection 140 mg in 1 mL single use pre-filled pen, Injection 420 mg in 3.5 mL single use pre-filled cartridge; Repatha®
- Fluocinolone acetonide: Intravitreal injection 190 micrograms; Iluvien®
- Galcanezumab (chronic migraine): Injection 120 mg in 1 mL pre-filled pen; Emgality®
- Galcanezumab (episodic migraine): Injection 120 mg in 1 mL pre-filled pen; Emgality®
- Glecaprevir and pibrentasvir: Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir; Maviret®
- Guselkumab: Injection 100 mg in 1 mL single use pre-filled syringe, Injection 100 mg in 1 mL single use pre-filled pen; Tremfya®
- High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral liquid 250 mL, 30; Ketovie 4:1®; Ketovie 3:1®; Ketovie Peptide 4:1®
- Ibrutinib: Tablet 140 mg, Tablet 280 mg, Tablet 420 mg, Tablet 560 mg; Imbruvica®
- Infliximab: Injection 120 mg in 1 mL pre-filled syringe, Injection 120 mg in 1 mL pre-filled pen: Remsima® SC
- Ixazomib: Capsule 2.3 mg, Capsule 3 mg, Capsule 4 mg; Ninlaro®
- Larotrectinib: Capsule 25 mg; Capsule 100 mg; Oral solution 20 mg per mL, 100 mL; Vitrakvi®
- Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine: Injection 0.5 mL; Menquadfi®
- Mesalazine: Tablet 1600 mg; Asacol®
- Mogamulizumab: Solution concentrate for I.V. infusion 20 mg in 5 mL; Poteligeo®
- Nivolumab and Ipilimumab; Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL Yervoy®
- Nusinersen: Solution for injection 12 mg in 5 mL: Spinraza®
- Obeticholic acid: Tablet 5 mg, Tablet 10 mg; Ocaliva®
- Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma®
- Pancreatic extract: Capsule (containing enteric coated minimicrospheres) providing not less than 20,000 bp units of lipase activity, Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 bp units of lipase activity; Creon®
- Patiromer: Sachet, 8.4 g powder for oral liquid; Sachet, 16.8 g powder for oral liquid; Veltassa®
- Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Progesterone: Capsule 200 mg; Utrogestan®
- Progesterone: Pessary 200 mg; Oripro®
- Ribociclib: Tablet 200 mg: Kisqali®
- Sacubitril with valsartan; Tablet containing sacubitril 24.3 mg and valsartan 25.7 mg, Tablet containing sacubitril 48.6 mg and valsartan 51.4 mg, Tablet containing sacubitril 97.2 mg and valsartan 102.8 mg; Entresto®
- Sapropterin: Powder for oral solution 500 mg, Tablet (soluble) 100 mg; Kuvan®
- Secukinumab: Injection 150 mg in 1 mL pre-filled pen; Cosentyx®
- Tofacitinib: Tablet 5 mg, Tablet 10 mg; Xeljanz®
- Tofacitinib (ulcerative colitis): Tablet 5 mg, Tablet 10 mg: Xeljanz®
- Upadacitinib: Tablet 15 mg; Rinvoq®
- Vedolizumab: Injection 108 mg in 0.68 mL pre-filled syringe, Injection 108 mg in 0.68 mL pre-filled pen; Entyvio®
The following Public Summary Documents have been updated.
July 2018 PBAC meeting
November 2019 PBAC meeting
July 2020 PBAC meeting
- Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL, Solution concentrate for I.V. infusion 840 mg in 14 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin®
- Cannabidiol: Oral solution, 100 mg per mL, 100 mL; Epidyolex®
- Indacaterol with Glycopyrronium and Mometasone: Capsule containing powder for oralinhalation mometasone furoate 80 micrograms with indacaterol 150 micrograms (as acetate)with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler), Capsule containing powder for oral inhalation mometasone furoate 160 micrograms with indacaterol 150micrograms (as acetate) with glycopyrronium 50 micrograms (as bromide) (for use inBreezhaler); Enerzair Breezhaler®
